Phaseline

Targets › TF

TF (Serotransferrin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Jan 2028.

Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. (UniProt, P02787)

Open in Phaseline: the race on TF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prothya BiosolutionsHuman apotransferrin
Transferrin replacement protein
TFPhase 2Congenital AtransferrinemiaJan 2028

Conditions

Congenital Atransferrinemia (1)

Modalities

small molecule (1)

Companies

Prothya Biosolutions (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.